Matrix metalloproteinases in neuropathic pain and migraine: Friends, enemies, and therapeutic targets

Pain Research and Treatment

Volumn 2012, Issue , 2012, Pages

  Lakhan, Shaheen E ^a   Avramut, Mihaela ^a,b  

^a Global Neuroscience Initiative Foundation   (United States)

^b Verland Medical Communications   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873824414     PISSN: 20901542     EISSN: 20901550     Source Type: Journal    
DOI: 10.1155/2012/952906     Document Type: Review

References (93)

1. Page-McCaw A., Ewald A. J., Werb Z., Matrix metalloproteinases and the regulation of tissue remodelling. Nature Reviews Molecular Cell Biology 2007 8 3 221 233 2-s2.0-33847195428 10.1038/nrm2125
2. Yong V. W., Metalloproteinases: mediators of pathology and regeneration in the CNS. Nature Reviews Neuroscience 2005 6 12 931 944 2-s2.0-28644435880 10.1038/nrn1807 (Pubitemid 41753087)
3. Yong V. W., Agrawal S. M., Stirling D. P., Targeting MMPs in acute and chronic neurological conditions. Neurotherapeutics 2007 4 4 580 589 2-s2.0-34848923138 10.1016/j.nurt.2007.07.005 (Pubitemid 47499287)
4. Yan C., Boyd D. D., Regulation of matrix metalloproteinase expression expression. Journal of Cellular Physiology 2007 211 1 19 26 2-s2.0-33847683870 10.1002/jcp.20948 (Pubitemid 46363892)
5. Ji R. R., Xu Z. Z., Wang X., Lo E. H., Matrix metalloprotease regulation of neuropathic pain. Trends in Pharmacological Sciences 2009 30 7 336 340 2-s2.0-67649394340 10.1016/j.tips.2009.04.002
6. Nuttall R. K., Silva C., Hader W., Bar-Or A., Patel K. D., Edwards D. R., Yong V. W., Metalloproteinases are enriched in microglia compared with leukocytes and they regulate cytokine levels in activated microglia. GLIA 2007 55 5 516 526 2-s2.0-33847723000 10.1002/glia.20478 (Pubitemid 46383181)
7. Vaillant C., Meissirel C., Mutin M., Belin M. F., Lund L. R., Thomasset N., MMP-9 deficiency affects axonal outgrowth, migration, and apoptosis in the developing cerebellum. Molecular and Cellular Neuroscience 2003 24 2 395 408 2-s2.0-0142188658 10.1016/S1044-7431(03)00196-9 (Pubitemid 37311303)
8. Luo J., The role of matrix metalloproteinases in the morphogenesis of the cerebellar cortex. Cerebellum 2005 4 4 239 245 2-s2.0-33644796277 10.1080/14734220500247646 (Pubitemid 43861184)
9. Webber C. A., Hocking J. C., Yong V. W., Stange C. L., McFarlane S., Metalloproteases and guidance of retinal axons in the developing visual system. Journal of Neuroscience 2002 22 18 8091 8100 2-s2.0-0037107138 (Pubitemid 35379115)
10. Soler R. C., Gui Y. H., Linask K. K., Muschel R. J., MMP-9 (gelatinase B) mRNA is expressed during mouse neurogenesis and may be associated with vascularization. Developmental Brain Research 1995 88 1 37 52 2-s2.0-0029113115 10.1016/0165-3806(95)00079-S
11. Hayashita-Kinoh H., Kinoh H., Okada A., Komori K., Itoh Y., Chiba T., Kajita M., Yana I., Seiki M., Membrane-type 5 matrix metalloproteinase is expressed in differentiated neurons and regulates axonal growth. Cell Growth and Differentiation 2001 12 11 573 580 2-s2.0-0035189968 (Pubitemid 33095580)
12. Jaworski D. M., Fager N., Regulation of tissue inhibitor of metalloproteinase-3 (Timp-3) mRNA expression during rat CNS development. Journal of Neuroscience Research 2000 61 4 396 408 (Pubitemid 30620225)
13. Larsen P. H., DaSilva A. G., Conant K., Yong V. W., Myelin formation during development of the CNS is delayed in matrix metalloproteinase-9 and -12 null mice. Journal of Neuroscience 2006 26 8 2207 2214 2-s2.0-33645643179 10.1523/JNEUROSCI.1880-05.2006 (Pubitemid 44699029)
14. Dzwonek J., Rylski M., Kaczmarek L., Matrix metalloproteinases and their endogenous inhibitors in neuronal physiology of the adult brain. FEBS Letters 2004 567 1 129 135 2-s2.0-2542436756 10.1016/j.febslet.2004.03.070 (Pubitemid 38686435)
15. Meighan S. E., Meighan P. C., Choudhury P., Davis C. J., Olson M. L., Zornes P. A., Wright J. W., Harding J. W., Effects of extracellular matrix-degrading proteases matrix metalloproteinases 3 and 9 on spatial learning and synaptic plasticity. Journal of Neurochemistry 2006 96 5 1227 1241 2-s2.0-33645103421 10.1111/j.1471-4159.2005.03565.x
16. Nagy V., Bozdagi O., Matynia A., Balcerzyk M., Okulski P., Dzwonek J., Costa R. M., Silva A. J., Kaczmarek L., Huntley G. W., Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. Journal of Neuroscience 2006 26 7 1923 1934 2-s2.0-33644522107 10.1523/JNEUROSCI.4359-05.2006
17. Larsen P. H., Wells J. E., Stallcup W. B., Opdenakker G., Yong V. W., Matrix Metalloproteinase-9 Facilitates Remyelination in Part by Processing the Inhibitory NG2 Proteoglycan. Journal of Neuroscience 2003 23 35 11127 11135 2-s2.0-0346749451 (Pubitemid 37548948)
18. Hsu J. Y. C., McKeon R., Goussev S., Werb Z., Lee J. U., Trivedi A., Noble-Haeusslein L. J., Matrix metalloproteinase-2 facilitates wound healing events that promote functional recovery after spinal cord injury. Journal of Neuroscience 2006 26 39 9841 9850 2-s2.0-33749174156 10.1523/JNEUROSCI.1993-06. 2006 (Pubitemid 44477146)
19. Pizzi M. A., Crowe M. J., Transplantation of fibroblasts that overexpress matrix metalloproteinase-3 into the site of spinal cord injury in rats. Journal of Neurotrauma 2006 23 12 1750 1765 2-s2.0-33845932921 10.1089/neu.2006.23.1750 (Pubitemid 46034449)
20. Zhang Y., Klassen H. J., Tucker B. A., Perez M. T. R., Young M. J., CNS progenitor cells promote a permissive environment for neurite outgrowth via a matrix metalloproteinase-2-dependent mechanism. Journal of Neuroscience 2007 27 17 4499 4506 2-s2.0-34247494789 10.1523/JNEUROSCI.0200-07.2007 (Pubitemid 46663570)
21. Zhao B. Q., Wang S., Kim H. Y., Storrie H., Rosen B. R., Mooney D. J., Wang X., Lo E. H., Role of matrix metalloproteinases in delayed cortical responses after stroke. Nature Medicine 2006 12 4 441 445 2-s2.0-33645744014 10.1038/nm1387
22. Zhao B. Q., Tejima E., Lo E. H., Neurovascular proteases in brain injury, hemorrhage and remodeling after stroke. Stroke 2007 38 2 748 752 2-s2.0-33846694043 10.1161/01.STR.0000253500.32979.d1 (Pubitemid 46188254)
23. Yong V. W., Zabad R. K., Agrawal S., Goncalves DaSilva A., Metz L. M., Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators. Journal of the Neurological Sciences 2007 259 1-2 79 84 2-s2.0-34447104602 10.1016/j.jns.2006.11.021 (Pubitemid 47031205)
24. Weaver A., Goncalves da Silva A., Nuttall R. K., Edwards D. R., Shapiro S. D., Rivest S., Yong V. W., An elevated matrix metalloproteinase (MMP) in an animal model of multiple sclerosis is protective by affecting Th1/Th2 polarization. FASEB Journal 2005 19 12 1668 1670 2-s2.0-26444447974 10.1096/fj.04-2030fje (Pubitemid 41429524)
25. Noble L. J., Donovan F., Igarashi T., Goussev S., Werb Z., Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events. Journal of Neuroscience 2002 22 17 7526 7535 2-s2.0-0036758650 (Pubitemid 35386354)
26. Wells J. E. A., Rice T. K., Nuttall R. K., Edwards D. R., Zekki H., Rivest S., Yong V. W., An adverse role for matrix metalloproteinase 12 after spinal cord injury in mice. Journal of Neuroscience 2003 23 31 10107 10115 2-s2.0-0242442568 (Pubitemid 37392558)
27. Lee S. R., Tsuji K., Lee S. R., Lo E. H., Role of matrix metalloproteinases in delayed neuronal damage after transient global cerebral ischemia. Journal of Neuroscience 2004 24 3 671 678 2-s2.0-0842327251 10.1523/JNEUROSCI.4243-03.2004 (Pubitemid 38166493)
28. Leppert D., Leib S. L., Grygar C., Miller K. M., Schaad U. B., Holländer G. A., Matrix metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: association with blood-brain barrier damage and neurological sequelae. Clinical Infectious Diseases 2000 31 1 80 84 2-s2.0-0034455606 10.1086/313922 (Pubitemid 32268943)
29. Rosenberg G. A., Kornfeld M., Estrada E., Kelley R. O., Liotta L. A., Stetler-Stevenson W. G., TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Research 1992 576 2 203 207 2-s2.0-0026558127 10.1016/0006-8993(92)90681-X
30. Manicone A. M., McGuire J. K., Matrix metalloproteinases as modulators of inflammation. Seminars in Cell and Developmental Biology 2008 19 1 34 41 2-s2.0-36849094431 10.1016/j.semcdb.2007.07.003 (Pubitemid 350235986)
31. Leppert D., Waubant E., Galardy R., Bunnett N. W., Hauser S. L., T cell gelatinases madiate basement membrane transmigration in vitro. Journal of Immunology 1995 154 9 4379 4389 2-s2.0-0029041446
32. Chandler S., Miller K. M., Clements J. M., Lury J., Corkill D., Anthony D. C. C., Adams S. E., Gearing A. J. H., Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. Journal of Neuroimmunology 1997 72 2 155 161 2-s2.0-0031040486 10.1016/S0165-5728(96)00179-8 (Pubitemid 27062771)
33. Cunningham L. A., Wetzel M., Rosenberg G. A., Multiple roles for MMPs and TIMPs in cerebral ischemia. GLIA 2005 50 4 329 339 2-s2.0-20344373695 10.1002/glia.20169 (Pubitemid 40780839)
34. Opdenakker G., Nelissen I., Van Damme J., Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis. The Lancet Neurology 2003 2 12 747 756 2-s2.0-0344420053 10.1016/S1474-4422(03) 00587-8 (Pubitemid 37443517)
35. Scholz J., Woolf C. J., The neuropathic pain triad: neurons, immune cells and glia. Nature Neuroscience 2007 10 11 1361 1368 2-s2.0-35548937457 10.1038/nn1992 (Pubitemid 350014681)
36. Folgueras A. R., Valdés-Sánchez T., Llano E., Menéndez L., Baamonde A., Denlinger B. L., Belmonte C., Juárez L., Lastra A., García-Suárez O., Astudillo A., Kirstein M., Pendás A. M., Fariñas I., López-Otín C., Metalloproteinase MT5-MMP is an essential modulator of neuro-immune interactions in thermal pain stimulation. Proceedings of the National Academy of Sciences of the United States of America 2009 106 38 16451 16456 2-s2.0-70349487751 10.1073/pnas.0908507106
37. Christianson C. A., Fitzsimmons B. L., Shim J. H., Agrawal A., Cohen S. M., Hua X. Y., Yaksh T. L., Spinal matrix metalloproteinase 3 mediates inflammatory hyperalgesia via a tumor necrosis factor-dependent mechanism. Neuroscience 2012 200 199 210 10.1016/j.neuroscience.2011.10.019
38. Kobayashi H., Chattopadhyay S., Kato K., Dolkas J., Kikuchi S. I., Myers R. R., Shubayev V. I., MMPs initiate Schwann cell-mediated MBP degradation and mechanical nociception after nerve damage. Molecular and Cellular Neuroscience 2008 39 4 619 627 2-s2.0-56249117978 10.1016/j.mcn.2008.08.008
39. Kawasaki Y., Zhang L., Cheng J. K., Ji R. R., Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1 β interleukin-6, and tumor necrosis factor- α in regulating synaptic and neuronal activity in the superficial spinal cord. Journal of Neuroscience 2008 28 20 5189 5194 2-s2.0-45549090676 10.1523/JNEUROSCI.3338-07.2008
40. Kim Y., Remacle A. G., Chernov A. V., Liu H., Shubayev I., Lai C., Dolkas J., Shiryaev S. A., Golubkov V. S., Mizisin A. P., The MMP-9/TIMP-1 axis controls the status of differentiation and function of myelin-forming Schwann cells in nerve regeneration. PLoS ONE 2012 7 3 e33664
41. Kawasaki Y., Xu Z. Z., Wang X., Park J. Y., Zhuang Z. Y., Tan P. H., Gao Y. J., Roy K., Corfas G., Lo E. H., Ji R. R., Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nature Medicine 2008 14 3 331 336 2-s2.0-40449126196 10.1038/nm1723 (Pubitemid 351347915)
42. Sommer C., Kress M., Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neuroscience Letters 2004 361 1-3 184 187 2-s2.0-2342646193 10.1016/j.neulet. 2003.12.007 (Pubitemid 38609247)
43. Woolf C. J., Mannion R. J., Neuropathic pain: aetiology, symptoms, mechanisms, and management. The Lancet 1999 353 9168 1959 1964 2-s2.0-0033526651 10.1016/S0140-6736(99)01307-0 (Pubitemid 29255720)
44. Zhuang Z. Y., Gerner P., Woolf C. J., Ji R. R., ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain 2005 114 1-2 149 159 2-s2.0-14044252008 10.1016/j.pain.2004.12.022 (Pubitemid 40279096)
45. Zhang H., Chang M., Hansen C. N., Basso D. M., Noble-Haeusslein L. J., Role of matrix metalloproteinases and therapeutic benefits of their inhibition in spinal cord injury. Neurotherapeutics 2011 8 2 206 220 2-s2.0-79955071242 10.1007/s13311-011-0038-0
46. Fernandes K. S., Brum D. G., Palei A. C., Sandrim V. C., Guerreiro C. T., Tanus-Santos J. E., Barreira A. A., Functional MMP-9 polymorphisms modulate plasma MMP-9 levels in multiple sclerosis patients. Journal of Neuroimmunology 2012 249 1-2 56 59 10.1016/j.jneuroim.2012.04.001
47. Zahednasab H., Saadatnia M., Jabalameli M. R., Zarkesh-Esfahani H., Esmaeili A., Bahreini S. A., Controversial role of MMP-9 gene in MS disease. Journal of Neuroimmunology 2011 230 1-2 191 2-s2.0-78650966095 10.1016/j.jneuroim.2010.09.006
48. Créange A., Sharshar T., Raphaël J. C., Gherardi R., Cellular aspect of neuroinflammation in Guillain-Barré syndrome: a key to a new therapeutic option? Revue Neurologique 2002 158 1 15 27 2-s2.0-17744405695 (Pubitemid 34145518)
49. Leppert D., Hughes P., Huber S., Erne B., Grygar C., Said G., Miller K. M., Steck A. J., Probst A., Fuhr P., Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy. Neurology 1999 53 1 62 70 2-s2.0-0033551469 (Pubitemid 29329650)
50. Gurer G., Erdem S., Kocaefe C., Özgüç M., Tan E., Expression of matrix metalloproteinases in vasculitic neuropathy. Rheumatology International 2004 24 5 255 259 2-s2.0-4644344980 10.1007/s00296-003-0380-6 (Pubitemid 39286904)
51. Robak E., Wierzbowska A., Chmiela M., Kulczycka L., Sysa-Jdrejowska A., Robak T., Circulating total and active metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in patients with systemic lupus erythomatosus. Mediators of Inflammation 2006 2006 7 2-s2.0-33645220368 10.1155/MI/2006/17898 17898
52. Mawrin C., Brunn A., Röcken C., Schröder J. M., Peripheral neuropathy in systemic lupus erythematosus: pathomorphological features and distribution pattern of matrix metalloproteinases. Acta Neuropathologica 2003 105 4 365 372 2-s2.0-0038439394 (Pubitemid 36805577)
53. Renaud S., Erne B., Fuhr P., Said G., Lacroix C., Steck A. J., Leppert D., Matrix metalloproteinases-9 and -2 in secondary vasculitic neuropathies. Acta Neuropathologica 2003 105 1 37 42 2-s2.0-0037484263 (Pubitemid 36798015)
54. Chandler S., Coates R., Gearing A., Lury J., Wells G., Bone E., Matrix metalloproteinases degrade myelin basic protein. Neuroscience Letters 1995 201 3 223 226 2-s2.0-0029586166 10.1016/0304-3940(95)12173-0 (Pubitemid 26009985)
55. Devor M., Sodium channels and mechanisms of neuropathic pain. Journal of Pain 2006 7 1, supplement S3 S12 2-s2.0-30844469806 10.1016/j.jpain.2005.09.006 (Pubitemid 43106683)
56. Ji R. R., Strichartz G., Cell signaling and the genesis of neuropathic pain. Science's STKE 2004 2004 252 reE14 2-s2.0-7944238825
57. Calvo M., Bennett D. L., The mechanisms of microgliosis and pain following peripheral nerve injury. Experimental Neurology 2012 234 2 271 282 10.1016/j.expneurol.2011.08.018
58. Shubayev V. I., Myers R. R., Matrix metalloproteinase-9 promotes nerve growth factor-induced neurite elongation but not new sprout formation in vitro. Journal of Neuroscience Research 2004 77 2 229 239 2-s2.0-3042794125 10.1002/jnr.20160 (Pubitemid 38859407)
59. Zuo J., Ferguson T. A., Hernandez Y. J., Stetler-Stevenson W. G., Muir D., Neuronal matrix metalloproteinase-2 degrades and inactivates a neurite- inhibiting chondroitin sulfate proteoglycan. Journal of Neuroscience 1998 18 14 5203 5211 2-s2.0-0032527889 (Pubitemid 28311937)
60. Khojasteh F., Hasanpour-Ezati M., Mirnajafi-Zadeh J., Semnanian S., Role of matrix metalloproteinase II in the analgesia induced by neuronal nitric oxide inhibition in rat. Physiology and Pharmacology 2009 13 1 10 17 2-s2.0-77957886386
61. Yamamoto T., Saito O., Shono K., Ohtori S., Ino H., Analgesic effect of intrathecally administered matrix metalloproteinase 2 (MMP-2) in the rat formalin test. Neuroscience Letters 2003 347 2 77 80 2-s2.0-0038302389 10.1016/S0304-3940(03)00668-2 (Pubitemid 36836220)
62. Nishida K., Kuchiiwa S., Oiso S., Futagawa T., Masuda S., Takeda Y., Yamada K., Up-regulation of matrix metalloproteinase-3 in the dorsal root ganglion of rats with paclitaxel-induced neuropathy. Cancer Science 2008 99 8 1618 1625 2-s2.0-49749085552 10.1111/j.1349-7006.2008.00877.x
63. Komori K., Nonaka T., Okada A., Kinoh H., Hayashita-Kinoh H., Yoshida N., Yana I., Seiki M., Absence of mechanical allodynia and A β -fiber sprouting after sciatic nerve injury in mice lacking membrane-type 5 matrix metalloproteinase. FEBS Letters 2004 557 1-3 125 128 2-s2.0-1642573173 10.1016/S0014-5793(03)01458-3 (Pubitemid 38115881)
64. Rodriguez Parkitna J., Korostynski M., Kaminska-Chowaniec D., Obara I., Mika J., Przewlocka B., Przewlocki R., Comparison of gene expression profiles in neuropathic and inflammatory pain. Journal of Physiology and Pharmacology 2006 57 3 401 414 2-s2.0-33749616591 (Pubitemid 44543875)
65. Siddall P. J., McClelland J. M., Rutkowski S. B., Cousins M. J., A longitudinal study of the prevalence and characteristics of pain in the first 5 years following spinal cord injury. Pain 2003 103 3 249 257 2-s2.0-0037683297 10.1016/S0304-3959(02)00452-9 (Pubitemid 36638814)
66. Detloff M. R., Fisher L. C., McGaughy V., Longbrake E. E., Popovich P. G., Basso D. M., Remote activation of microglia and pro-inflammatory cytokines predict the onset and severity of below-level neuropathic pain after spinal cord injury in rats. Experimental Neurology 2008 212 2 337 347 2-s2.0-47349092661 10.1016/j.expneurol.2008.04.009
67. Rice A. S. C., Farquhar-Smith W. P., Nagy I., Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukotrienes and Essential Fatty Acids 2002 66 2-3 243 256 2-s2.0-0036019404 10.1054/plef.2001.0362 (Pubitemid 34743599)
68. Ramer R., Hinz B., Cyclooxygenase-2 and tissue inhibitor of matrix metalloproteinases-1 confer the antimigratory effect of cannabinoids on human trabecular meshwork cells. Biochemical Pharmacology 2010 80 6 846 857 2-s2.0-77954760593 10.1016/j.bcp.2010.05.010
69. Li W. H., Lee Y. M., Kim J. Y., Kang S., Kim S., Kim K. H., Park C. H., Chung J. H., Transient receptor potential vanilloid-1 mediates heat-shock-induced matrix metalloproteinase-1 expression in human epidermal keratinocytes. Journal of Investigative Dermatology 2007 127 10 2328 2335 2-s2.0-34848828195 10.1038/sj.jid.5700880 (Pubitemid 47619755)
70. Dombourian M. G., Turner N. A., Gerovac T. A., Vemuganti R., Miranpuri G. S., Türeyen K., Satriotomo I., Miletic V., Resnick D. K., B1 and TRPV-1 receptor genes and their relationship to hyperalgesia following spinal cord injury. Spine 2006 31 24 2778 2782 2-s2.0-33751099585 10.1097/01.brs.0000245865. 97424.b4 (Pubitemid 44772776)
71. Cutrer F. M., Charles A., The neurogenic basis of migraine. Headache 2008 48 9 1411 1414 2-s2.0-53849088203 10.1111/j.1526-4610.2008.01277.x
72. Dalkara T., Nozari A., Moskowitz M. A., Migraine aura pathophysiology: the role of blood vessels and microembolisation. The Lancet Neurology 2010 9 3 309 317 2-s2.0-76449092082 10.1016/S1474-4422(09)70358-8
73. Gursoy-Ozdemir Y., Qiu J., Matsuoka N., Bolay H., Bermpohl D., Jin H., Wang X., Rosenberg G. A., Lo E. H., Moskowitz M. A., Cortical spreading depression activates and upregulates MMP-9. Journal of Clinical Investigation 2004 113 10 1447 1455 2-s2.0-2942615488 10.1172/JCI200421227 (Pubitemid 39071700)
74. Richter F., Lehmenkühler A., Cortical spreading depression (CSD): a neurophysiological correlate of migraine aura. Schmerz 2008 22 5 544 550 2-s2.0-52549132169 10.1007/s00482-008-0653-9
75. Gupta V. K., CSD, BBB and MMP-9 elevations: animal experiments versus clinical phenomena in migraine. Expert Review of Neurotherapeutics 2009 9 11 1595 1614 2-s2.0-70849105632 10.1586/ern.09.103
76. Imamura K., Takeshima T., Fusayasu E., Nakashima K., Increased plasma matrix metalloproteinase-9 levels in migraineurs. Headache 2008 48 1 135 139 2-s2.0-37549040237 10.1111/j.1526-4610.2007.00958.x
77. Martins-Oliveira A., Speciali J. G., Dach F., Marcaccini A. M., Gonçalves F. M., Gerlach R. F., Tanus-Santos J. E., Different circulating metalloproteinases profiles in women with migraine with and without aura. Clinica Chimica Acta 2009 408 1-2 60 64 2-s2.0-69849106717 10.1016/j.cca.2009. 07.008
78. Leira R., Sobrino T., Rodríguez-Yáñez M., Blanco M., Arias S., Castillo J., MMP-9 immunoreactivity in acute migraine. Headache 2007 47 5 698 702 2-s2.0-34248370099 10.1111/j.1526-4610.2006.00641.x (Pubitemid 46733712)
79. Ashina M., Tvedskov J. F., Lipka K., Bilello J., Penkowa M., Olesen J., Matrix metalloproteinases during and outside of migraine attacks without aura. Cephalalgia 2010 30 3 303 310 2-s2.0-77956251264 10.1111/j.1468-2982.2009.01954. x
80. Bernecker C., Pailer S., Kieslinger P., Horejsi R., Möller R., Lechner A., Wallner-Blazek M., Weiss S., Fazekas F., Truschnig-Wilders M., Gruber H. J., Increased matrix metalloproteinase activity is associated with migraine and migraine-related metabolic dysfunctions. European Journal of Neurology 2011 18 4 571 576 2-s2.0-79952731303 10.1111/j.1468-1331.2010.03205.x
81. Yong V. W., Wells J., Giuliani F., Casha S., Power C., Metz L. M., The promise of minocycline in neurology. The Lancet Neurology 2004 3 12 744 751 2-s2.0-8844254741 10.1016/S1474-4422(04)00937-8 (Pubitemid 39535260)
82. Hu J., Van den Steen P. E., Sang Q. X. A., Opdenakker G., Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nature Reviews Drug Discovery 2007 6 6 480 498 2-s2.0-34447520043 10.1038/nrd2308 (Pubitemid 47064570)
83. Jacobsen J. A., Major Jourden J. L., Miller M. T., Cohen S. M., To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition. Biochimica et Biophysica Acta 2010 1803 1 72 94 2-s2.0-77149131528 10.1016/j.bbamcr.2009.08.006
84. Peterson J. T., Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Failure Reviews 2004 9 1 63 79 2-s2.0-1042263796 10.1023/B:HREV.0000011395.11179.af (Pubitemid 38202142)
85. Griffioen A. W., AG-3340 agouron pharmaceuticals inc. IDrugs 2000 3 3 336 345 2-s2.0-0006315176
86. Yu F., Kamada H., Niizuma K., Endo H., Chan P. H., Induction of MMP-9 expression and endothelial injury by oxidative stress after spinal cord injury. Journal of Neurotrauma 2008 25 3 184 195 2-s2.0-40949153084 10.1089/neu.2007. 0438 (Pubitemid 351416743)
87. Gu Z., Cui J., Brown S., Fridman R., Mobashery S., Strongin A. Y., Lipton S. A., A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. Journal of Neuroscience 2005 25 27 6401 6408 2-s2.0-21844450866 10.1523/JNEUROSCI.1563-05.2005 (Pubitemid 40962536)
88. Gooyit M., Lee M., Schroeder V. A., Ikejiri M., Suckow M. A., Mobashery S., Chang M., Selective water-soluble gelatinase inhibitor prodrugs. Journal of Medicinal Chemistry 2011 54 19 6676 6690 10.1021/jm200566e
89. Wojtowicz-Praga S., Clinical potential of matrix metalloprotease inhibitors. Drugs in R D 1999 1 2 117 129 2-s2.0-0033070874
90. Solorzano C. C., Ksontini R., Pruitt J. H., Hess P. J., Edwards P. D., Kaibara A., Abouhamze A., Auffenberg T., Galardy R. E., Vauthey J. N., Copeland E. M., Edwards C. K., Lauwers G. Y., Clare-Salzler M., MacKay S. L. D., Moldawer L. L., Lazarus D. D., Involvement of 26-kDa cell-associated TNF- α in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor. Journal of Immunology 1997 158 1 414 419 2-s2.0-0030638944 (Pubitemid 127483883)
91. Gordon P. H., Moore D. H., Miller R. G., Florence J. M., Verheijde J. L., Doorish C., Hilton J. F., Spitalny G. M., MacArthur R. B., Mitsumoto H., Neville H. E., Boylan K., Mozaffar T., Belsh J. M., Ravits J., Bedlack R. S., Graves M. C., McCluskey L. F., Barohn R. J., Tandan R., Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. The Lancet Neurology 2007 6 12 1045 1053 2-s2.0-36148960127 10.1016/S1474- 4422(07)70270-3 (Pubitemid 350116691)
92. Khiat A., D'Amour M., Souchon F., Boulanger Y., MRS study of the effects of minocycline on markers of neuronal and microglial integrity in ALS. Magnetic Resonance Imaging 2010 28 10 1456 1460 2-s2.0-78449254316 10.1016/j.mri.2010.06. 032
93. Gim G. T., Lee J. H., Park E., Sung Y. H., Kim C. J., Hwang W. W., Chu J. P., Min B. I., Electroacupuncture attenuates mechanical and warm allodynia through suppression of spinal glial activation in a rat model of neuropathic pain. Brain Research Bulletin 2011 86 5-6 403 411 10.1016/j.brainresbull.2011. 09.010